This startup develops translational biomarkers to accelerate the discovery of disease-modifying drugs for Alzheimer's disease and related dementias. Their programs leverage human patient genetics, tau biology, and neuroinflammation research to identify biomarkers that inform clinical strategy, monitor disease progression, and assess treatment response.
Funding
Funding not disclosed
Founders
Product
Problem
The development of effective treatments for Alzheimer's disease and related dementias (ADRD) is hindered by a lack of translational biomarkers that can accurately identify appropriate patients, monitor disease progression, and assess treatment response. This deficiency results in inefficient clinical trials and delays the availability of disease-modifying drugs.
Solution
Monument Biosciences is developing a new generation of translational biomarkers to accelerate the discovery and development of disease-modifying drugs for ADRD. Their approach leverages human patient genetics, recent advances in tau biology and tau seeding, and insights into the role of microglia in neuroinflammation. By focusing on these key areas, Monument Biosciences aims to identify biomarkers that can inform clinical strategy, monitor disease progression, and evaluate the efficacy of novel therapies. These biomarkers will enable the selection of the right patients for clinical trials and facilitate the development of more effective treatments for ADRD.
Target Audience
The primary target audience includes pharmaceutical companies, clinical researchers, and other organizations involved in the discovery and development of therapeutics for Alzheimer's disease and related dementias.
Features
- Discovery programs anchored in human patient genetics to identify novel drug targets
- Focus on tau homeostasis and tau seeding mechanisms relevant to Alzheimer's disease pathology
- Investigation of the role of microglia and neuroinflammation in disease progression
- Development of translational biomarkers to predict and monitor treatment response
- Exploration of diverse therapeutic modalities and potential combination therapies